uniQure N.V. - Ordinary Shares (QURE)
26.06
-4.38 (-14.39%)
NASDAQ · Last Trade: Nov 5th, 6:26 PM EST
Detailed Quote
| Previous Close | 30.44 |
|---|---|
| Open | 27.55 |
| Bid | 25.61 |
| Ask | 25.80 |
| Day's Range | 25.52 - 27.99 |
| 52 Week Range | 5.350 - 71.50 |
| Volume | 8,926,289 |
| Market Cap | 1.43B |
| PE Ratio (TTM) | -6.648 |
| EPS (TTM) | -3.9 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 4,107,044 |
Chart
About uniQure N.V. - Ordinary Shares (QURE)
Uniqure is a biotechnology company focusing on the development of gene therapies for the treatment of genetic diseases. The company is dedicated to creating innovative and transformative therapies that target various conditions, particularly those related to genetic disorders and rare diseases. By leveraging advanced gene-editing technologies, Uniqure aims to provide long-lasting solutions that address the underlying causes of these ailments. Their pipeline includes research and development efforts centered on delivering effective treatments to improve patients' lives through the unique potential of gene therapy. Read More
News & Press Releases
Biohaven stock plunged after the FDA rejected Vyglxia for spinocerebellar ataxia, prompting major R&D cuts and a William Blair downgrade.
Via Benzinga · November 5, 2025
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In uniQure (QURE) To Contact Him Directly To Discuss Their Options
By Bragar Eagel & Squire · Via GlobeNewswire · November 5, 2025
LOS ANGELES, Nov. 05, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of uniQure N.V. (“uniQure” or “the Company”) (NASDAQ: QURE) for violations of the securities laws.
By Schall Law · Via GlobeNewswire · November 5, 2025
uniQure Stock Tumbled 56% Today: What’s The FDA Angle?stocktwits.com
Via Stocktwits · November 3, 2025
The company was nearing approval for a treatment for a rare, neurodegenerative disease. Then, the FDA spoke.
Via Investor's Business Daily · November 5, 2025
Via Benzinga · November 5, 2025
Via Benzinga · November 5, 2025
NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against uniQure N.V. (“uniQure” or the “Company”) (NASDAQ:QURE). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices.
By Kirby McInerney LLP · Via GlobeNewswire · November 4, 2025
William Blair notes FDA's tougher stance on gene therapy programs as AMT-130 faces uncertainty in its accelerated approval timeline.
Via Benzinga · November 4, 2025
The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of uniQure N.V. (NASDAQ: QURE) (“uniQure”).
By Kessler Topaz Meltzer & Check, LLP · Via Business Wire · November 4, 2025
Via Benzinga · November 4, 2025
Via Benzinga · November 4, 2025
Via Benzinga · November 4, 2025
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
Via Chartmill · November 3, 2025
Stay up-to-date with the latest market trends one hour before the close of the markets on Monday. Explore the top gainers and losers during today's session in our detailed report.
Via Chartmill · November 3, 2025
Via Benzinga · November 3, 2025
UniQure shares fell after the FDA questioned the adequacy of data supporting its AMT-130 gene therapy for Huntington's disease, delaying BLA plans.
Via Benzinga · November 3, 2025
Stay up-to-date with the latest market trends in the middle of the day on Monday. Explore the top gainers and losers during today's session in our detailed report.
Via Chartmill · November 3, 2025
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of uniQure N.V. (“uniQure” or “the Company”) (NASDAQ: QURE) for violations of the securities laws.
By The Schall Law Firm · Via Business Wire · November 3, 2025
Via Benzinga · November 3, 2025
In today's session, there are notable price gaps in the US markets on Monday. Take a closer look at the stocks that are gap up and gap down.
Via Chartmill · November 3, 2025
The DJS Law Group announces that it is investigating claims on behalf of investors of uniQure N.V. (“uniQure” or “the Company”) (NASDAQ: QURE) for violations of the securities laws.
By The DJS Law Group · Via Business Wire · November 3, 2025
Via Benzinga · November 3, 2025
An analyst described the FDA feedback as "confusing" and "unexpected" for the experimental Huntington's disease treatment.
Via Investor's Business Daily · November 3, 2025
As we await the opening of the US market on Monday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.
Via Chartmill · November 3, 2025